⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline
globenewswire.com
AMGN
JNJ
XNCR
Xencor to Present at the 2026 Cantor Global Healthcare Conference
businesswire.com
XNCR
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Multispecific Antibodies Market Report 2026: Forecast to Reach $60 Billion by 2031, Driven by Expanding Clinical Pipeline and Proprietary Technologies
globenewswire.com
AMGN
JNJ
PFE
REGN
MRK
ABBV
BMY
GILD
AZN
XNCR
GEN
ABL
Global Fusion Biopsy Market to Register Sustainable Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
BSX
CAH
MDT
GEHC
XRAY
AMGN
AZN
BMY
LLY
MRK
PFE
SNY
TEVA
JNJ
BIIB
GILD
NVS
GOOG
MSFT
IBM
NVDA
INTC
AMD
QCOM
AMAT
MU
NXPI
ASML
ADI
LRCX
KLAC
CDNS
SNPS
MCHP
ON
STM
MRVL
AEHR
TER
PAYX
CTAS
WST
ZBRA
VRSN
NOW
CRM
ADBE
PANW
CSCO
ACN
HPQ
ORCL
SAP
PTC
ALGN
ESTC
DDOG
SMCI
EXAS
CRSP
EDIT
BEAM
NTLA
REGN
VRTX
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
IQ
BILI
VIPS
HTHT
EDU
TAL
MELI
AMZN
NFLX
DIS
CMCSA
VZ
T
SIRI
GOOGL
AAPL
META
TSLA
GE
PHI
BRKR
AUR
FONR
BFLY
CRI
EXEL
TAK
ABSI
JHG
XNCR
MOD
ARVN
CLAR
BNTX
FOR
ORIC
COOK
OWL
MTA
SKIN
HYPR
ALLT
MAGN
Form 8-K
sec.gov
XNCR
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
prnewswire.com
AZN
BIIB
XNCR
Form 8-K
sec.gov
XNCR
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
businesswire.com
XNCR
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
businesswire.com
XNCR